Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml-1).

Liu J, Wang ZQ, Li M, Zhou MY, Yu YF, Zhan WW.

Asian J Androl. 2019 Jun 4. doi: 10.4103/aja.aja_46_19. [Epub ahead of print]

2.

Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.

Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M.

J Urol. 2000 Apr;163(4):1144-8; discussion 1148-9.

PMID:
10737484
3.

Prostate specific antigen density of the transition zone for early detection of prostate cancer.

Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M.

J Urol. 1998 Aug;160(2):411-8; discussion 418-9.

PMID:
9679889
4.

Utility of the transition zone index for identification of prostate cancer in Chinese men with intermediate PSA levels.

Qi TY, Chen YQ, Jiang J, Zhu YK, Yao XH, Wang XJ.

Int Urol Nephrol. 2012 Jun;44(3):807-15. doi: 10.1007/s11255-011-0119-3. Epub 2012 Feb 5.

PMID:
22311386
5.

Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.

Nakano Y, Okamura K, Takamura S, Okamoto N, Narishima M, Yoshino Y, Hattori R, Ono Y, Ohshima S, Nagasaka T.

Int J Urol. 2005 Aug;12(8):721-7.

6.

Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.

Salido-Guadarrama AI, Morales-Montor JG, Rangel-Escareño C, Langley E, Peralta-Zaragoza O, Cruz Colin JL, Rodriguez-Dorantes M.

Mol Med Rep. 2016 Jun;13(6):4549-60. doi: 10.3892/mmr.2016.5095. Epub 2016 Apr 8.

7.

[Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer].

Martínez Jabaloyas JM, García Morata F, Villamón Fort R, Pastor Hernández F, Gil Salom M, García Sisamón F.

Actas Urol Esp. 2003 Jun;27(6):442-9. Spanish.

PMID:
12918151
9.

[Analysis of influential factors for prostate biopsy and establishment of logistic regression model for 
prostate cancer].

Li Y, Tang Z, Qi L, Chen Z, Li D, Zeng M, Xue R, Peng C.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015 Jun;40(6):651-6. doi: 10.11817/j.issn.1672-7347.2015.06.013. Chinese.

10.

Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.

Okegawa T, Kinjo M, Ohta M, Miura I, Horie S, Nutahara K, Higashihara E.

Int J Urol. 2003 Apr;10(4):201-6.

11.

Multigene methylation analysis for detection and staging of prostate cancer.

Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Clin Cancer Res. 2005 Sep 15;11(18):6582-8.

12.
13.

Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: development of a novel pre-biopsy nomogram.

Ohigashi T, Kanao K, Mizuno R, Kikuchi E, Nakashima J, Oya M.

Int J Urol. 2010 Mar;17(3):274-80. doi: 10.1111/j.1442-2042.2010.02453.x. Epub 2010 Feb 10.

14.
15.

Determination of the relative probability for prostate cancer to avoid unnecessary biopsy.

Okamura K, Takaba H, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Nagasaka T.

Int J Urol. 2005 Apr;12(4):346-52.

16.

Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate-specific antigen levels of 2.0-10.0 ng/mL.

Kobayashi T, Mitsumori K, Kawahara T, Nishizawa K, Ogura K, Ide Y.

Int J Urol. 2005 Nov;12(11):969-75.

17.

The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population.

Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y.

Jpn J Clin Oncol. 2004 Oct;34(10):602-7.

PMID:
15591458
18.

Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?

Xu N, Wu YP, Chen DN, Ke ZB, Cai H, Wei Y, Zheng QS, Huang JB, Li XD, Xue XY.

J Cancer Res Clin Oncol. 2018 May;144(5):987-995. doi: 10.1007/s00432-018-2616-6. Epub 2018 Mar 5.

PMID:
29504080
19.

Clinical usefulness of free PSA in early detection of prostate cancer.

Luboldt HJ, Swoboda A, Börgermann C, Fornara P, Rübben H; Early Detection Project Group of the German Society of Urology.

Onkologie. 2001 Feb;24(1):33-7.

PMID:
11441278
20.

Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL.

Li XM, Zhang L, Li J, Li Y, Wang HL, Ji GY, Kuwahara M, Zhao XJ.

Asian J Androl. 2005 Sep;7(3):323-8.

Supplemental Content

Support Center